RUNX1 and metabolic dysfunction-associated steatohepatitis: A decrease in the hepatic CCL2 and TNF-α levels in RUNX1 siRNA-treated animals demonstrated that the silencing of RUNX1 is an important strategy to target the release of inflammatory mediators by LSECs in NASH liver.